Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

RSS icon

ACA replacement plan advances without changes after marathon hearing

It took until the wee hours of the morning, but Republicans advanced part of their replacement legislation for the Affordable Care Act (ACA) without making any changes to the original bill in the House Ways and Means Committee.

Conservatives plan their own ACA replacement bill

Objecting to the American Health Care Act (ACHA) introduced by Republican leaders in the House, conservative lawmakers have pledged to introduce their own alternative to the Affordable Care Act (ACA). 

Thumbnail

‘Critically flawed’: Industry groups blast Republican ACA replacement

The initial reaction to the American Health Care Act (AHCA), the legislation to repeal and replace the Affordable Care Act (ACA) introduced by Republican leaders in Congress and supported by President Donald Trump, is negative across several major medical organizations, including the American Medical Association and the Federation of American Hospitals. 

5 things hospitals, insurers should know about Republicans' ACA replacement

House Republicans have released the full text of the long-awaited legislation to repeal and replace the Affordable Care Act (ACA). Titled the “American Health Care Act (AHCA),” the bill would eliminate the ACA’s mandate for individuals to buy insurance and roll back the expansion of Medicaid, while restoring disproportionate share hospital (DSH) payments.

Thumbnail

ACA replacement plan expected to be detailed this week

A legislative aide, speaking to Reuters on condition of anonymity, said there have been a series of phone calls finalizing the Affordable Care Act (ACA) replacement plan involving Speaker Paul Ryan, HHS Secretary Tom Price, White House budget chief Mick Mulvaney, President Donald Trump’s domestic policy adviser Andrew Bremberg and others.

HHS Secretary Price doesn’t rule out Medicare changes

HHS Secretary Tom Price said the Trump administration and Republicans “believe in the guarantee of Medicare for our seniors,” but he wouldn’t promise there would be no cuts to the program in an interview on CBS's “Face the Nation.”

Thumbnail

ACA’s future hot topic at HIMSS 2017—but HIMSS itself doesn’t take a stance

Many panels at HIMSS 2017 in Orlando included references to the ongoing policy debate over the Affordable Care Act (ACA) and how that’s affecting all corners of the industry. For HIMSS itself, however, it feels health IT is better off staying out of much of the discussion.

Thumbnail

No more meaningful use? MedPAC floats idea in MACRA discussion

Physicians wouldn’t be measured on meaningful use of electronic health records (EHRs) in the new Merit-based Incentive Payment System (MIPS) under a proposal floated by the Medicare Payment Advisory Commission (MedPAC).

Displaying 2065 - 2072 of 2772

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup